D. Tolzman

Tacrolimus with Mycophenolate Mofetil (MMF) or Sirolimus vs. Cyclosporine with MMF in Cardiac Transplant Patients: 1‐Year Report

G. Ewald, S. Russell, L. Miller, 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Prospective risk stratification in renal transplant candidates for cardiac death.

W. Bennett, J. Barry, D. Norman, 1994, American journal of kidney diseases : the official journal of the National Kidney Foundation.

RANDOMIZED TRIAL OF TACROLIMUS PLUS MYCOPHENOLATE MOFETIL OR AZATHIOPRINE VERSUS CYCLOSPORINE ORAL SOLUTION (MODIFIED) PLUS MYCOPHENOLATE MOFETIL AFTER CADAVERIC KIDNEY TRANSPLANTATION: RESULTS AT 2 YEARS1

M. Stegall, G. Danovitch, P. Halloran, 2001, Transplantation.

Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation.

M. Stegall, G. Danovitch, P. Halloran, 2000, Transplantation.

Incidence and type of cancer following the use of OKT3: a single center experience with 557 organ transplants.

W. Bennett, J. Barry, D. Norman, 1993, Transplantation proceedings.

THE ROLE OF ANTIBODY INDUCTION IN SIMULTANEOUS PANCREAS KIDNEY (SPK) TRANSPLANT PATIENTS RECEIVING TACROLIMUS + MYCOPHENOLATE MOFETIL (MMF) IMMUNOSUPPRESSION.: Abstract# 357

M. Stegall, R. Merion, G. Danovitch, 2000 .